Shed Platform Adds Oral GLP-1 Access

Shed, an online health and wellness platform, has expanded its offerings by incorporating Foundayo™, also known as orforglipron. This medication is Eli Lilly and Company's oral GLP-1 treatment, designed for managing conditions like type 2 diabetes and obesity. The addition of Foundayo™ provides patients nationwide with greater access to this innovative therapeutic option through Shed's digital health services. This move aligns with the growing trend of telehealth and digital platforms enhancing patient access to advanced medical treatments.